Age-specific PCA3 score reference values for diagnosis of prostate cancer

World Journal of Urology

Volumn 30, Issue 3, 2012, Pages 405-410

  Klatte, Tobias ^a   Waldert, Matthias ^a   de Martino, Michela ^a   Schatzl, Georg ^a   Mannhalter, Christine ^a   Remzi, Mesut ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Landesklinikum Weinviertel ^*  (Austria)

Author keywords

Accuracy; Age; AUC; Decision curve; Prostate biopsy; Prostate cancer; Prostate cancer gene 3 (PCA3); PSA

Indexed keywords

PROSTATE CANCER ANTIGEN 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

AGED; AGING; ARTICLE; BIOPSY; BLOOD; COHORT ANALYSIS; DECISION SUPPORT SYSTEM; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROSTATE TUMOR; REFERENCE VALUE; RETROSPECTIVE STUDY; STATISTICAL MODEL;

AGED; AGING; ANTIGENS, NEOPLASM; BIOPSY; COHORT STUDIES; DECISION SUPPORT TECHNIQUES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84861611602     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-011-0749-1     Document Type: Article

References (29)

1. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59: 61-71.
2. Stephan C, Kramer J, Meyer HA, Kristiansen G, Ziemer S, Deger S, Lein M, Loening SA, Jung K (2007) Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 99: 1427-1431.
3. Ponholzer A, Temml C, Madersbacher S (2010) Has blood volume an impact on serum PSA levels? World J Urol 28: 693-697.
4. Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schröder FH (2008) The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 68: 985-993.
5. Evans CP (2009) Identification of molecular targets in urologic oncology. World J Urol 27: 3-8.
6. Prior C, Guillen-Grima F, Robles JE, Rosell D, Fernandez-Montero JM, Agirre X, Catena R, Calvo A (2010) Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol 28: 681-686.
7. Herrmann TR, Merseburger AS, Burchardt M (2010) Prostate cancer: novel aspects of diagnostics and surgical technology. World J Urol 28: 665.
8. Durand X, Moutereau S, Xylinas E, de la Taille A (2011) Progensa PCA3 test for prostate cancer. Expert Rev Mol Diagn 11: 137-144.
9. de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, Gontero P, Mottaz A, Haese A (2011) Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 185: 2119-2125.
10. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA (2008) Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54: 1081-1088.
11. Remzi M, Haese A, van Poppel H, de la Taille A, Stenzl A, Hennenlotter J, Marberger M (2010) Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int 106: 1138-1142.
12. Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster R, Andriole GL, Groskopf J (2010) PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 184: 1947-1952.
13. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J (2007) PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69: 532-535.
14. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J (2008) PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179: 1587-1592.
15. Tombal B, Ameye F, de la Taille A, de Reijke T, Gontero P, Haese A, Kil P, Perrin P, Remzi M, Schroder J, Speakman M, Volpe A, Meesen B, Stoevelaar H (2011) Biopsy and treatment decisions in the initial management of prostate cancer and the role of PCA3; a systematic analysis of expert opinion. World J Urol. doi: 10. 1007/s00345-00011-00721-00340 (in press).
16. Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, Nicolaiew N, Terry S, Allory Y, Loric S, Salomon L, Vacherot F, de la Taille A (2011) Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 59: 422-429.
17. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, Davis JW, Troncoso P, Rittenhouse H, Babaian RJ (2008) PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179: 1804-1810.
18. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG (2008) PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180: 1975-1978, discussion 1978-1979.
19. Liss MA, Santos R, Osann K, Lau A, Ahlering TE, Ornstein DK (2010) PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol. doi: 10. 1007/s00345-00010-00623-00346 (in press).
20. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993) Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864.
21. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 international society of urological pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma. Am J Surg Pathol 29: 1228-1242.
22. Vickers AJ, Elkin EB (2006) Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 26: 565-574.
23. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, Luger F, Gutschi S, Budaus L, Fisch M, Huland H, Graefen M, Haese A (2011) Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 59: 96-105.
24. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Haese A (2009) Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 56: 659-667.
25. Bianchi-Frias D, Vakar-Lopez F, Coleman IM, Plymate SR, Reed MJ, Nelson PS (2010) The effects of aging on the molecular and cellular composition of the prostate microenvironment. PLoS One 5: e12501.
26. Morote J, Rigau M, Garcia M, Mir C, Ballesteros C, Planas J, Raventos CX, Placer J, de Torres IM, Reventos J, Doll A (2010) Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World J Urol 28: 677-680.
27. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT (2009) Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 115: 3879-3886.
28. Lee MC, Moussa AS, Yu C, Kattan MW, Magi-Galluzzi C, Jones JS (2010) Multifocal high grade prostatic intraepithelial neoplasia is a risk factor for subsequent prostate cancer. J Urol 184: 1958-1962.
29. Auprich M, Haese A, Walz J, Pummer K, de la Taille A, Graefen M, de Reijke T, Fisch M, Kil P, Gontero P, Irani J, Chun FK (2010) External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 58: 727-732.